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Abstract
It is generally accepted that bacteria in biofilm are more resistant to antibacterials than
their planktonic counterparts. For numerous antibiotics, it has been shown that minimal
inhibitory concentrations (MICs) for bacteria grown in broth are much lower than the
minimal biofilm inhibition concentrations. While sub‐inhibitory concentrations, that is,
amounts of antibacterials below the MIC, do not either influence or suppress to some
extent or other the bacterial growth in liquid media, these same amounts of drugs, natural
substances, etc., may have diverse effects on bacterial biofilms, ranging from suppres‐
sion to stimulation of the sessile growth and varying with regard to the bacterial species
and strains. This is a source of additional risks for both biofilm infection of host tissues
and contamination indwelling devices. When considering the data for biofilm modula‐
tion, differences in experimental protocols should be taken into account, as well as the
strain‐specific mechanisms of biofilm formation.
Keywords: biofilm, sub‐MIC, antibiotics, bacteriocins, antimicrobial peptides, plant
metabolites
1. Introduction
While the development of antibiotics during the twentieth century resulted in remarkable
advances in the fight against infectious microorganisms, it was unfortunately paralleled with
the highly increasing risks for the development of antibiotic resistance. These risks are a
consequence of the extensive use of antibacterial preparations in both human medicine and
agriculture. Resistance has become a threat to human and animal health worldwide, and it
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necessitates the development of key measures. Among these, the identification of critical points
of control, the development of surveillance measures, and the prevention of environmental
contamination are in focus [1].
In the aquatic and terrestrial environments, the contaminated sites (wastewater systems,
pharmaceutical factories effluents, animal husbandry facilities, etc.) are characterized by the
presence of subtherapeutic concentrations of antibiotics [1–3]. Thus, bacteria present in the
environment are often subjected to drug amounts lower than the minimal inhibitory concen‐
trations (MICs) [4]. Antimicrobial sub‐MICs are encountered in the human body as well,
during treatment, which can occur irregularly at intervals at the site of infection [5] or in
cases of low‐dose antibiotic prophylaxis [6]. When microorganisms grow in the presence of
sub‐MICs, the antibiotics can potentially alter the physicochemical characteristics of micro‐
bial cells, their functions, and the expression of some virulence genes [7]. While sub‐MICs
generally do not interfere with bacterial growth dynamics, the microorganisms are subjected
to stress. As a way to counter stress, microbes would often form biofilms both in external
environments and on indwelling medical devices [3, 8, 9].
It is noteworthy that, when MICs or sub‐MICs are considered, this concerns values obtained
with bacteria grown in liquid media, that is, as plankton. Such will be the use of the term
also in the present review. In biofilms, the inhibitory doses exceed 10 to even 1000 times
these of plankton [1, 9, 10]. Interestingly, when plankton and bacteria dispersed from bio‐
film have been examined, they were shown to have similar antibiotic susceptibility [11].
Hence, increased resistance is likely associated with characteristics that are a consequence of
the structure of the sessile microbial communities. They themselves represent heterologous
microenvironments in which gradients of physical and chemical parameters exist [3]. The
advantages of these structured bacterial communities comprise limited antibiotic diffusion,
enhanced transmission of resistance genes, expression of efflux pumps, drug adsorption by
extracellular matrix, as well as the presence of metabolically inactive persister cells [12].
Provided the growing concern about the wide spread and the role of environments contain‐
ing subinhibitory amounts of antibacterials, the present review will focus on the interplay of
sub‐MICs with biofilm growth and/or detachment. In a previous review, the antibiotic‐in‐
duced biofilm formation has been discussed [13]. However, the sub‐MIC of antibiotics, but
also other antibacterials (e.g. antibacterial peptides, natural and synthetic substances, etc.),
dependent on the combination drug‐bacterial strain or species, may have diverse effects on
biofilm, from suppression through no effect to promotion. This determined the aim of the
present review: to summarize current data and concepts about the modulation of biofilm
growth by sub‐MICs of antibacterial substances.
2. Sub‐MIC of antibiotics and biofilms
While it was initially believed that antibiotics in nature have the role for fighting against
competitors, and that therefore also sub‐MICs would reduce virulence, recent evidence re‐
veals a more complicated picture, showing the capacity of some antibiotics at low dose to
act as chemical signals to modulate metabolic processes [14] or regulate gene (including vir‐
ulence gene) expression [15].
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The idea on the effects of antibiotic sub‐MICs on biofilms is getting more and more compli‐
cated with the accumulation of experimental data. This puts forward the question of method‐
ology. The conventional approaches to antibiotic sensitivity do not apply to biofilm‐grown
bacteria [9]. Due to the potentially very high intrinsic biofilm resistance, the focus has mainly
been put on their prevention [16]. Probably for this reason, most results have been obtained
while applying the drug during the sessile growth, with only a few studies testing the agent's
effects on pre‐formed biofilms [17–19]. The routinely applied methodology is to test biofilm
biomass on 96‐well plates by the crystal violet assay, with only a few other studies that explore
cell viability as well, for example, the viable cell counts [20] or live‐dead staining for fluores‐
cence microscopy.
We have summarized the available experimental data on the action of sub‐MICs of antibiot‐
ics on biofilms in Table 1–5. We could find no strict pattern with regard to the effects of the
separate groups of antibiotics. All groups were shown to influence some biofilms positively,
and others, negatively. An important observation is the bacterial species and strain specifici‐
ty of the response to the sub‐MICs. Thus, sub‐MICs of ampicillin increased biofilm growth of
Staphylococcus saprophyticus [6], reduced it in Escherichia coli K‐12 [21], and had no effect on E.
coli UTI8 and Mycobacterium avium [6, 22] (Table 1). Sub‐MICs of ciprofloxacin promoted
biofilms of S. saprophyticus [6] and E. coli UTI8 [6], but reduction was registered in Streptococ‐
cus suis, Salmonella enterica serovar Typhimurium clinical strains, Stenotrophomonas maltophil‐
ia, Streptococcus pyogenes, Staphylococcus epidermidis, and Proteus mirabilis [17, 18, 20, 23–25]
(Table 2). Diverse effects have been illustrated for sub‐MICs of erythromycin on biofilms of S.
suis, Corynebacterium diphtheriae, and S. epidermidis [25–27] (Table 3); for gentamycin on S.
enterica serovar Typhimurium, S. saprophyticus, E. coli, Haemophilus influenzae, Staphylococcus
aureus, and Pseudomonas aeruginosa (Table 4); and for tetracyclin on E. coli, Staphylococcus
lugdunensis, M. avium, P. aeruginosa, and S. epidermidis [9, 15, 21, 22, 28] (Table 5).
Antibiotics Amount Bacteria/strains Effect on biofilm Ref.
Penicillins
Dicloxacillin 1/2 MIC S. epidermidis strains 9142, IE186, and M187 32–60% BF inhibition [29]
8 μg/ml S. epidermidis M187
S. haemolyticus M176
BF biomass reduction; decreased synthesis of the EPS,
poly‐N‐acetyl‐glucosamine
[16]
Penicillin 1/16–1/2 MICS. suis NJ‐3 Dose‐dependent BF suppression [25]
1/8 MIC C. diphtheriae subsp. mitis strains No effect [26]
Methicillin 1/3–1/8 MIC S. aureus Newman Denser BF formed by the strain and its small‐colony
variants
[30]
Nafcillin 0.0625–0.5
MIC
S. lugdunensis—15 isolates from BF‐related
infections (endocarditis, prosthetic joint
infections, etc.)
Increase in 93% of the tested strains, no effect in 7% [9]
1/3–1/8 MIC S. aureus Newman No effect on BF [30]
Cephalosporins
Cefazolin 1/2 MIC S. epidermidis strains 9142, IE186, and M187 32–55% BF inhibition [29]
0.0625–0.5
MIC
S. lugdunensis—15 isolates from BF‐related
infections (endocarditis, prosthetic joint
infections, etc.)
Increase in 13% of the tested strains, no effect in 80%, and
decrease in 7%
[9]
0.5 MIC S. epidermidis strains SE5 and RP62A BF decrease [31]
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Antibiotics Amount Bacteria/strains Effect on biofilm Ref.
Cefalotin 1/3–1/8 MIC S. aureus Newman Three‐ to fourfold denser BF formed by the strain and its
small‐colony variants
[30]
Cefoperazone 1/3–1/8 MIC S. aureus Newman No effect on BF [30]
Cefotaxime 1/2–1/16 MICSalmonella enterica serovar Typhimurium
clinical isolates 75 strains
At 1/2 MIC—significantly increased production of BF and
EPS
[5]
Ampicillin 0.005–500
μg/ml
E. coli MG1655 wt and MG1655 (pBR322) BF reduction [21]
0.1–1.1 μg/mlS. saprophyticus 15305 Sub‐MIC (0.3–0.7 μg/ml) stimulate BF formation [6]
1/2–1/1024
MIC
E. coli UTI89 BF stimulation at MIC, no effect of
sub‐MIC
[6]
10 μg/l M. avium strains 104; 101, A5; 3362‐33 and
3362‐34)
No effect on BF [22]
Carbapenems
Imipenem 2–4 μg/ml P. aeruginosa PA01 BF induction, changes in BF morphology, upregulation of
ampC and genes for alginate biosynthesis
[32]
0.03 and
0.125 μg/ml
73 isolates A. baumannii BF stimulation [33]
Ceftazidime 1/2–1/8 MIC 5 clinical isolates strains S. maltophilia BF inhibition and reduction of viable cell counts [20]
0.125–1.0
MIC
5 strains P. mirabilis BF inhibition [24]
2; 8; 32 mg/l 6 clinical isolates of P. aeruginosa Synergistic effect with polymorphonuclears against
developed 48 h BF
[34]
Abbreviations: BF, biofilm; EPS, exopolysaccharide; MIC, minimal inhibitory concentration.
Table 1. Effects of sub‐MIC of β‐lactam antibiotics on biofilms.
Antibiotics Amount Bacteria/strains Effect on biofilm Ref.
Ciprofloxacin 1/16–1/2 MIC S. suis NJ‐3 Dose‐dependent BF suppression [25]
1/2–1/16MIC Salmonella enterica serovar
Typhimurium clinical isolates 75
strains
Inhibition of BF formation and EPS
synthesis
[5]
0.1–1.1 μg/ml S. saprophyticus 15305 BF stimulation by sub‐MIC (0.4–0.9 μg/ml) [6]
1/2–1/1024 MIC E. coli UTI89 Statistically significant BF increase and
upregulation of BF‐associated genes at 1/4
MIC
[6]
1/2–1/8MIC 5 clinical isolates S. maltophilia BF inhibition and reduction of viable cell
counts
[20]
1/2–1/64 MIC S. pyogenes isolates (M56; st38;M89;
M65; M100; M74)
Dose‐dependent BF inhibition [23]
0.5 × MIC E. coli strains (8; 9; 10; 31 ;1583) Reduction of BF formation and survival of
the BF bacteria
[18]
1/2–1/8 MIC Staphylococcus epidermidis—20
clinical isolates
Reduces BF growth and pre‐formed BF [17]
0.125–1.0 MIC 5 strains P. mirabilis BF inhibition [24]
2; 8; 32 mg/l MIC P. aeruginosa—6 clinical isolates Synergistic effect with
polymorphonuclears against developed 48‐
h BF
[32]
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Antibiotics Amount Bacteria/strains Effect on biofilm Ref.
0.001–100 mg/l P. aeruginosa BF reduction [15]
Norfloxacin 1–10,000 mg/l S. aureus ATCC 25923 BF stimulation by 1 mg/l [8]
1–10,000 mg/l P. aeruginosa NNRL‐B3509 BF stimulation by 1 mg/l [8]
1/2–1/8 MIC S. maltophilia—5 clinical isolates
strains
BF inhibition and reduction of viable cell
counts
[20]
1/2–1/64 MIC S. pyogenes isolates (M56; st38;M89;
M65; M100; M74)
Dose‐dependent BF inhibition [23]
1/2–1/8 MIC Staphylococcus epidermidis—20
clinical isolates
Suppression of BF growth and reduction of
pre‐formed BF
[17]
1/16–1/2 MIC S. suis NJ‐3 Dose‐dependent biofilm suppression [25]
Ofloxacin 1/2–1/8MIC S. maltophilia—5 clinical isolates
strains
BF inhibition and reduction of viable cell
counts
[20]
1/2–1/64 MIC S. pyogenes isolates (M56; st38;M89;
M65; M100; M74)
Dose‐dependent BF inhibition [23]
0.5 × MIC S. epidermidis strains (SE5; RP62A) No effect on BF formation [31]
1/2–1/8 MIC Staphylococcus epidermidis—20
clinical isolates
Suppression of BF growth and reduction of
pre‐formed BF
[17]
1/2–1/8 MIC S. maltophilia—5 clinical isolates
strains
Biofilm inhibition and reduction of viable
cell counts
[20]
Levofloxacin 1/2–1/64 MIC S. pyogenes isolates (M56; st38;
M89; M65; M100; M74)
Dose‐dependent BF inhibition [23]
0.0625– 0.5 MIC S. lugdunensis—15 isolates from
biofilm‐related infections
(endocarditis, prosthetic joint
infections, etc.)
Increase in 20% of the tested strains, in 47%
no effect, and in 40% decrease
[9]
Moxifloxacin 1 μg/l M. avium strains (104; 101; A5;
3362‐33; 3362‐34)
No effect on BF [22]
1/2–1/8 MIC S. maltophilia—5 clinical isolates
strains
BF inhibition and reduction of viable cell
counts
[20]
0.03–0.06 MIC S. maltophilia strains Sm 132 and
Sm 144
Decrease in adhesion and BF formation [7]
2; 10; 50; 100 x MICS. aureus—6 strains of coagulase
negative
No effect on BF [35]
1 μg/ml M. avium strains (101, 104, 109, and
A5)
BF inhibition [36]
1/2–1/8MIC S. maltophilia —5 clinical isolates
strains
BF inhibition and reduction of viable cell
counts
[20]
Grepafloxacin 1/2–1/8MIC S. maltophilia—5 clinical isolates
strains
BF inhibition and reduction of viable cell
counts
[20]
Pefloxacin 1/2–1/8 MIC S. epidermidis—20 clinical isolates Reduces BF growth and pre‐formed BF [17]
Table 2. Effects of sub‐MIC of fluoroquinolones on biofilms.
Antibiotics Amount Bacteria/strains Effect on biofilm Ref.
Erythromycin 1/16–1/2 MIC S. suis NJ‐3 Dose‐dependent BF suppression [25]
1/8 MIC C. diphtheriae subsp. mitis strains BF increase [26]
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Antibiotics Amount Bacteria/strains Effect on biofilm Ref.
0.25 MIC S. epidermidis—96 clinical isolates BF inhibition in 4 strains; BF enhancement in
20, other strains—unaffected
[27]
Azithromycin 1/2–1/16 MIC S. suis NJ‐3 BF inhibition by 1/4 and 1/2 MIC [25]
2.5–10 mg/ml S. aureus strains (B1 487; B1 493; B1 412; B 391;
B1 468; B1 483; B1 379; B1 472)
BF reduction [37]
0.125 μg/ml H. influenzae NTHi2019 Decreased BF formation, reduction of
established BF
[19]
8 μg/m M. avium strains (101, 104, 109, and A5) BF inhibition [36]
sub‐MICs P. aeruginosa—35 clinical isolates Dose‐dependent BF reduction [38]
Clarithromycin 1 μg/ml M. avium strains (101, 104, 109, and A5) BF inhibition [36]
MIC b/n 50–550 mg/mlP. aeruginosa Sub‐MIC result in altered structure and
architecture of BF
[39]
Table 3. Effects of sub‐MIC of macrolides on biofilms.
Antibiotics Amount Bacteria/strains Effect on biofilm Ref.
Gentamycin 1/2–1/16 Salmonella enterica serovar
Typhimurium clinical isolates 75
strains
Inhibition of BF formation and EPS
synthesis
[25]
0.1–1.1 μg/ml S. saprophyticus 15305 Statistically significant BF
increase by 0.6—0.7 μg/ml
[6]
1/2–1/1024 MIC E. coli UTI89 Statistically significant BF
increase by 1/32 MIC
[6]
8 μg/ml H. influenzae NTHi2019 No effect on BF [19]
From sub‐MIC up to
100× MIC
S. aureus strains (RN6390 ATCC
25923)
BF increase [11]
0.1–1.5 μg/ml MIC P. aeruginosa PAK and isogenic
mutants
BF increase [40]
Streptomycin 0.5–2 μg/ml M. avium strains (104; 101; A5;
3362‐33; 3362‐34; 8G12; 5G4; 6H9)
BF increase, induction of
BF‐associated genes
[22]
Tobramycin 0.05–2 μg/ml P. aeruginosa PAK and isogenic
mutants
BF increase [40]
0.3; 0.5; 1.0 μg/ml Xylella fastidiosa ATCC 700964 and
3 isogenic mutants
BF reduction [41]
0.001–100 μg/l P. aeruginosa BF reduction [15]
Amikacin 0.5× MIC E. coli strains (8; 9; 10; 31; 1583) Reduction of BF formation
and survival of the BF‐bacteria
[18]
2; 8; 32 mg/l P. aeruginosa—6 clinical isolates Synergistic effect with
polymorphonuclears for
developed 48‐h BF
[32]
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Kanamycin 10–110 μg/ml P. aeruginosa PAK and isogenic
mutants
BF increase [40]
Table 4. Effects of sub‐MIC of aminoglycosides on biofilms.
Antibiotics Amount Bacteria/ strains Effect on biofilm Ref.
Streptogramins
Quinupristin‐dalfopristin
0.5 μg/ml S. epidermidis strains 567 and
S. epidermidis 561
Enhancement of icaADBC operon
expression and EPS synthesis
[28]
0.0625–0.5 MIC S. lugdunensis—15 isolates from biofilm‐related
infections (endocarditis, prosthetic joint
infections, etc.)
Increase in 20% of the tested strains; in
47% no effect and in 33% decrease
[9]
Glycopeptides
Vancomycin
1/2 MIC S. epidermidis strains 9142, IE186 and M187 8–24% BF inhibition [29]
0.0625–0.5 MIC S. lugdunensis—15 isolates from biofilm‐related
infections (endocarditis, prosthetic joint
infections, etc.)
Increase in 27% of the tested strains; in
47% no effect and in 27% decrease
[9]
0.5× MIC S. epidermidis strains SE5 and RP62A Decrease in BF [31]
Tetracyclins
Tetracyclin
0.005–500 μg/ml E. coli MG1655 wt and MG1655 (pBR322) Significant BF increase in the presence of
(pBR322)
[21]
0.0625–0.5 MIC S. lugdunensis—15 isolates from biofilm‐related
infections (endocarditis, prosthetic joint
infections, etc.)
Increase 7% of tested strains; decrease
93%
[9]
0.5–2 μg/ml M. avium strains (104; 101; A5; 3362‐33; 3362‐34)BF increase [22]
0.01–100 mg/l P. aeruginosa BF reduction [15]
0.5 μg/ml S. epidermidis strains 567 and
S. epidermidis 561
Enhancement of icaADBC operon
expression and EPS synthesis
[28]
DHFR inhibitors
Trimethroprim‐
sulfamethoxazole
0.0625–0.5 MIC S. lugdunensis—15 isolates from biofilm‐related
infections (endocarditis, prosthetic joint
infections, etc.)
Increase in 20% of the tested strains, in
40% no effect, and in 40% decrease
[9]
1/2–1/8 MIC 5 clinical isolates strains S. maltophilia BF inhibition and reduction of viable cell
counts
[20]
Oxazolidonones
Linezolid
0.0625–0.5 MIC S. lugdunensis—15 isolates from biofilm‐related
infections (endocarditis, prosthetic joint
infections, etc.)
In 80% no effect, in 20% decrease [9]
Table 5. Effects of sub‐MIC of streptogramins, glycopeptides, tetracyclins, dihydrofolate reductase (DHFR) inhibitors
and oxazolidonones on biofilms.
Antibiotics with identical mechanisms of antibacterial action, for example, gentamicin and
erythromycin, may have different effects on biofilm [19, 29]. In addition, the sub‐MICs of a
given antibiotic may have diverse effects on different strains of one species of microorgan‐
ism. For example, such is the case with the effects of cefazolin and levofloxacin on 15 isolates
of S. lugdunensis [9] (Table 1), the effects of erythromycin on 69 clinical isolates of S. epidermi‐
dis [27] (Table 3), of vancomycin on 3 strains of S. epidermidis and 15 isolates of S. lugdunensis
[9, 30] (Table 5), and of trimethoprim‐sulfamethoxazole on 15 isolates of S. lugdunensis [9]
(Table 5). Obviously, individual strains use different response mechanisms to oppose the
action of sub‐MICs [9].
Sub‐MICs of antibiotics have the potential to affect the structure of individual bacterial cells.
Changes of morphology have been registered in several studies. For instance, sub‐MIC of
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penicillin induced filamentation of cells of C. diphtheriae, while erythromycin reduced cell size
of this microorganism [26]. The sub‐MIC of the drug combination piperacillin/tazobactam
induced the occurrence of filamentous forms in P. aeruginosa, while subinhibitory amounts of
imipenem resulted in the formation of roundish forms (coccobacilli) of this bacterium [43].
Sub‐MICs of ciprofloxacin caused the occurrence of filamentous cells when applied to E. coli
isolated from urinary tract infections. This was accompanied by alterations in the morpholo‐
gy of the outer membrane cardiolipin domains of the strain [44]. The cell‐surface physico‐
chemical characteristics of the bacteria would also be affected. Several studies focus on cell‐
surface hydrophobicity. For example, sub‐MICs of penicillin and streptomycin which
enhanced biofilm formation in C. diphtheriae also rendered the cell surface more hydropho‐
bic [26]. The combination piperacillin/tazobactam applied as sub‐MIC that suppressed biofilm
growth also reduced cell‐surface hydrophobicity of P. aeruginosa [45]. While these examples
appear to show a likely positive correlation between cell‐surface hydrophobicity (which is also
related with cell adhesion) and the effects on biofilm growth, this may not be the rule
throughout. Thus, sub‐MICs of moxifloxacin that reduced biofilm growth had no influence on
the cell‐surface hydrophobicity of S. maltophilia [7]. Changes in zeta potential [8], flagellum‐
mediated swimming [45] and type IV fimbria‐related twitching motility [39, 45] have been
registered as well. When examined, the overall morphology of the biofilm, its thickness,
substratum coverage, and roughness would change as well [16, 39].
The extracellular biofilm matrix is an important component of these structured microbial
consortia. It has both structural and protective functions. In the interplay with the antibiotics,
its barrier role against drug penetration should be underlined [46]. For the time being, available
publications show a strict correlation between the effects of sub‐MICs on the biofilm and on
the extracellular matrix components. More data are available on the extracellular polysac‐
charide (EPS). In cases of biofilm biomass reduction (e.g. by gentamicin and ciprofloxacin on
S. Typhimurium, by fluoroquinolones on P. aeruginosa, and by dicloxacillin on S. epidermidis)
this was accompanied by reduced release of EPS [5, 16, 47]. In cases of biofilm biomass
increase (by sub‐MIC of erythromycin on S. epidermidis, of cefotaxime on S. enterica serovar
Typhimurium, and of azithromycin on representatives of several bacterial genera), this
coincided with EPS increase [5, 48, 49]. While less studied, such correlation might also
characterize another component of the extracellular matrix, the extracellular DNA. It was
registered with increased amounts in S. epidermidis biofilms treated with sub‐MICs of
vancomycin [50, 51].
Sub‐MICs of antibiotics can interact with the bacterial‐host interactions. Together with their
capacity to affect phenotypes, they can influence bacterial sensitivity to oxidative stress [45],
suppress host proinflammatory responses [6], and cooperate with host polymorphonuclear
leucocytes to destroy biofilms [34].
There is evidence that in nature, antibiotics at non‐inhibitory concentrations can have the role
of signalling molecules that can interfere with quorum sensing [4, 42]. It was shown that sub‐
MICs of antibiotics influence quorum‐sensing‐related phenotypes of Chromobacterium
violaceum, like the production of the pigment violacein, of acyl‐homoserine lactones, and of
chitinase [52]. Sub‐MICs of tobramycin inhibited the Rhl/R system of P. aeruginosa thus
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reducing the production of C4‐homoserine lactone [53]. Azithromycin also antagonized
quorum sensing in P. aeruginosa [4]. Cephalotin and cephalotaxime suppressed the agr
quorum‐sensing system in S. aureus [54].
Sub‐MICs of antibiotics can interact with bacterial regulation mechanisms and gene expres‐
sion. Transcriptomic studies indicated that the expression of approximately 5% of bacterial
promoters may be affected [13]. Genes related with antibiotic resistance should be men‐
tioned in the first place. There was a correlation between the transcription of the ermC gene
and the biofilm formation of erythromycin‐treated S. epidermidis [27]. In P. aeruginosa, among
the 34 genes influenced by imipenem, the most strongly induced gene was ampC coding for
chromosomal β‐lactamase [54]. Genes related with the synthesis of EPS or bacterial capsules
may be affected, like the genes from the icaADBC operon in S. epidermidis [28, 49]. Other genes
related with adhesion and biofilm development that should be mentioned are comD, gtfC, luxS,
gtfB, and atlA of Streptococcus mutans upregulated by sub‐MIC of triclosan [55] and guaB2 and
gtf in M. avium, upregulated under the action of sub‐MICs of streptomycin and tetracycline
[22]. The biofilm growth and detachment have been related with the intracellular levels of the
second messenger cyclic‐di‐GMP [40]. The eal gene participating in the pathways for its
synthesis was upregulated by sub‐MIC of tobramycin [41]. Definitely, the effects of sub‐MICs
on gene expression are not confined to these related to biofilm, many other genes can be
influenced as well [40].
3. Antibiofilm bacterial metabolites
The capacity of released metabolites of bacterial species and strains to modulate biofilm growth
of other bacteria is continuously in focus because of the potential for the isolation of novel
biofilm modulating substances. As an initial screening step, the action of cell‐free superna‐
tants (CFSs) is tested. The activities may vary from stimulation [56, 57] to suppression [58, 59].
Noteworthy, the effects of CFSs on bacterial growth in liquid media do not predict the effects
on sessile growth. Thus, subinhibitory amounts of 10-2 diluted CFSs from two bacteriocino‐
genic strains of Lactobacillus plantarum slowed down the growth of laboratory and uropatho‐
genic strains of E. coli, but stimulated significantly the biofilm development [59]. The active
substances in CFSs may be proteins/peptides, carbohydrates, low molecular weight metabo‐
lites, etc. [see comments by 57] and for some of them the nature, structure, and mode of action
have been explored. However, we shall restrict our review to molecules which have inhibito‐
ry activity on bacterial growth, and for which there is data on the effects of subinhibitory
amounts on biofilms.
Bacteriocins are proteins/peptides produced by prokaryotes which are active against other
bacterial species or strains. For example, colicins are produced by some strains of E. coli. One
of them, colicin M, is a phosphatase that hydrolyses the peptidoglycan lipid II intermediate,
thus interfering with peptidoglycan synthesis and causing cell lysis. In subinhibitory amounts,
it upregulated in P. aeruginosa PAO1 the ydeH gene related with the synthesis of cyclic‐di‐GMP,
as well as several biofilm‐related genes, ycfJ, rprA, omrA, and omrB. However, no biofilm
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stimulation was confirmed by the crystal violet assay [60]. RIP is an RNAIII‐inhibiting
heptapeptide originally isolated from CFS of Staphylococcus xylosus. It inhibits staphylococcal
pathogenesis. In sub‐MICs, it suppressed biofilm formation by interfering with the quorum‐
sensing mechanisms [61]. Nisin is a polycyclic antibacterial peptide produced by Lactococcus
lactis. At growth inhibitory concentrations, it suppressed sessile growth of S. aureus; howev‐
er, sub‐MICs had no effect on biofilm [62].
Mupirocin is an antibacterial substance of the monoxycarbolic acid class that was originally
isolated from Pseudomonas fluorescens. At sub‐MIC, it can reduce both biofilm formation and
glycocalyx production by P. aeruginosa [63]. Phenyl lactic acid is a metabolite of Lactobacillus
probiotic strains. At subinhibitory amounts, it attenuated the virulence and pathogenicity of
P. aeruginosa and S. aureus, including biofilm formation, by interacting with quorum sensing
[64]. The antifungal and antibacterial molecule, 2,4‐diacetylphloroglucinol, was isolated from
the CFS of Pseudomonas protegens. At subinhibitory amounts, it reduced pellicle and biofilm
formation, and sporulation of B. subtilis [65].
4. Antimicrobial peptides and biofilm modulation
The host‐bacterial interactions are also explored with the aim of identifying of novel mole‐
cules that would help overcoming the bacterial resistance mechanisms and combating
infections. One important group of substances is that of the antibacterial peptides, an impor‐
tant part of the innate immune system.
Colistin is a cationic antimicrobial peptide which is gaining importance in the fight against P.
aeruginosa cystic fibrosis infections. Subinhibitory concentrations altered the expression of 30
genes of the bacterium. Genes related with quorum sensing, lipopolysaccharides (LPSs)
modifications, quinolone biosynthesis, and biofilm formation were upregulated while genes
involved with motility and osmotolerance were downregulated. However, biofilm biomass
remained unaffected [66].
The major human host defence peptide LL‐37 is found in mucosal surfaces, the granules of
phagocytes, as well as in bodily fluids. At very low concentrations, far below those that kill or
inhibit the growth of P. aeruginosa, LL‐37 prevented the in vitro biofilm formation [67]. It
interfered with biofilm growth in at least three ways: by reduction of initial attachment,
promotion of twitching motility, and downregulation of key components of the Las and Rhl
quorum‐sensing systems [67].
The synthetic antimicrobial peptide 1018, derived from the bovine neutrophil defence peptide
bactenecin, has recently been identified as biofilm inhibitory compound. While not reflect‐
ing on bacterial growth, it could prevent the biofilm growth of P. aeruginosa, E. coli, Acineto‐
bacter baumannii, Klebsiella pneumoniae, S. enterica, Burkholderia cenocepacia, and methicillin‐
resistant S. aureus. This co‐related with degradation of ppGpp [68]. In addition, peptide 1018
acted in synergism with conventional antibiotics, like ceftazidime, ciprofloxacin, imipenem,
or tobramycin, to both prevent development and disperse existing biofilms [69].
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Invertebrate antibacterial responses are also explored. Thus, thanatin is an insect antimicro‐
bial peptide on the basis of which a shorter synthetic derivative, R‐thanatin, was synthe‐
sized. When applied in sub‐MIC amounts to S. epidermidis (including methicillin‐resistant
staphylococcus epidermidis, MRSE), Staphylococcus haemolyticus, and Staphylococcus hominis, it
inhibited biofilm formation. Parallelly, MRSE underwent serious morphological alterations
like swelling and abnormal divisions [70].
5. Subinhibitory amounts of plant substances
The application of plants for treatment of illness dates back to the very early moments of
mankind history, and has laid the basis of modern phytotherapy. The studies on the antibac‐
terial activities of medicinal plant products have a long tradition, more recently expanded to
biofilm research. Studies include tests on essential oils and plant extracts, partially purified
enriched fractions, as well as isolated pure substances. Also, plant products may be used as a
basis for chemical modifications aiming improved antibiofilm activity.
Among the plant products, essential oils are most popular for their wide use in ethnomedi‐
cine. Some of them that have antibacterial action proved successful against bacterial biofilms
as well. Among the essential oils that at subinhibitory amounts could suppress sessile growth
are, for example, these from Satureja hortensis L. (active against Prevotella nigrescens biofilm)
[71], from Thymus vulgaris (active against P. aeruginosa and E. coli biofilms) [72], and from
Mentha piperita (active against biofilms of P. aeruginosa and A. hydrophylla) [73]. In addition,
peppermint oil suppressed EPS production [73].
Methanol and aqueous branch extracts of five Juniperus sp. were examined for their activi‐
ties against two S. aureus strains. The extracts had minimal activity on planktonic growth of S.
aureus ATCC 3538P but suppressed biofilm formation, while the other strain, S. aureus 810,
was not affected in either mode of growth [74]. The extract from Leonurus cardiaca L. sup‐
pressed the adherence of S. aureus to both abiotic surfaces and surfaces covered with fibrino‐
gen, fibronectin, or collagen [75]. Sub‐MICs (1/2 to 1/32 MIC) of extracts from Boesenbergia
pandurata (Roxb.) Schltr. and Eleutherine americana Merr. significantly prevented biofilm
formation. Together with this, the extract from E. americana also suppressed quorum sensing
in C. violaceum test system [76].
In a study on 14 fractions from plant extracts, the total extract and the phenyl propanoid‐
containing fraction from Rhodiola rosea, and the total extract and the sesquiterpene lactone‐
containing fraction (Am2) from Arnica montana, were shown to have no antibacterial effects.
However, they suppressed the biofilm growth in E. coli urinary tract infection isolates. These
same extracts had the opposite effect—biofilm stimulation, on a multidrug‐resistant E. coli
strain isolated from asymptomatic bacteriuria [77]. Noteworthy, the sesquiterpene lactone‐
containing fraction Am2 also suppressed the quorum‐sensing‐controlled bioluminescence in
Vibrio harveyi bioreporter strains (ATCC1116 and ATCC1117) [78, 79].
Carvacol is an antimicrobial monotherpenic phenol with antibacterial potential that is present
in many essential oils. In subinhibitory doses, it suppressed sessile growth of a number of
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Gram‐positive and Gram‐negative bacteria [80, 81]. Polyphenols from muscadine grapes with
antioxidant and antibacterial activity, at 0.5 MIC, inhibited biofilm growth of S. aureus [82].
Similar was the effect of the essential oil components eugenol and citral on S. aureus and Listeria
monocytogenes [83], epigallocatechin‐3‐gallate from green tea on S. maltophilia [84], ursolic acid,
genistein, cranberry extract, p‐hydroxybenzoic acid, and resveratol on S. aureus [75, 85].
Menthol, together with biofilm suppression, was shown to inhibit both the las‐ and pqs‐related
quorum sensing [73].
Fenchone is a substance that is present in many essential oils. It had neither antibacterial nor
antibiofilm effects on a panel of Gram‐positive and Gram‐negative strains. This molecule was
used to synthesize its chemical derivatives. While the substitutions did not improve the
antibacterial properties against E. coli ATCC 25922 and six E. coli K‐12 strains, some of the
derivatives showed biofilm modulation potential [86]. Chalcones are a group of flavonoids
with antibacterial potential, found in many plants. Synthetic chalcones are applied as well. The
effects of sub‐MICs of three newly synthesized chalcones on methicillin‐resistant S. aureus were
examined. Both biofilm formation and adherence to human fibronectin were reduced, as well
as the release of EPS [87].
6. Other compounds with biofilm‐modulating potential
Other substances have also proved a good anti‐biofilm potential when applied in sub‐MICs.
For example, sodium ascorbate, together with suppressing P. aeruginosa virulence factors
(elastase, protease and haemolysin activities, pyocyanin production, and quorum sensing) also
reduced biofilm formation [88]. Biofilm growth was inhibited by subinhibitory amounts of
thiourea derivatives [89], thiazolinediones [90], and certain anthraquinones [91]. Organic
complexes of metals are also elaborated as antibacterial and/or antibiofilm substances. Newly
synthesized dimethylguanin‐copper complexes [92], the organo‐tellurium compound AS101
[93], and bismuth thiols [94] have shown anti‐biofilm activity at sub‐MICs. The latter substan‐
ces are considered as possible coating agents for indwelling devices. For prevention of medical
devices from bacterial contamination, other substances may prove useful as coating material,
like ovotransferrin, protamine sulfate, ethylenediaminetetraacetic acid (EDTA) [95], cerium
nitrate, chitosan, hamamelitannin [96], polyvinyl pyrrilidine [97], etc.
As an opposite effect, the biocides used in food processing facilities, trisodium phosphate,
sodium nitrite, and sodium hypochlorite, when applied in sub‐MICs, enhanced the capacity
of E. coli to form biofilms. This was accompanied by a reduction of the antibiotic susceptibili‐
ty [98].
7. Some final considerations
Presently, there is growing concern about the relationship between the rise of widespread
antibiotic resistance and the role of environments containing subinhibitory amounts of
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antibacterials [1]. As a major risk for human health, biofilm communities provide the bacte‐
ria with prerequisites for rapid resistance development [99]. Among the other more direct risks
that biofilms may cause to human health, should be mentioned the possibility for enhanced
colonization of indwelling medical devices in the presence of subinhibitory amounts of
antibacterial substances, and the contamination of surfaces in medical or food‐processing
environments. Depending on the aim of a given antibiofilm strategy, different effects may be
in the focus. Disinfection of outer surfaces in hospitals and in food industry requires that the
used agents have the capacity to detach established biofilms. On the opposite, if biofilms on
indwelling devices are concerned, once established, their detachment is hazardous. It may be
accompanied with dissemination of the bacteria to other sites in the human body, and there
are risks of sepsis [69]. Therefore, the development of medical materials should be directed to
biofilm prevention. However, when the effects of a given substance are estimated, the biology
of the biofilm as a whole is better to be addressed, starting from the attachment and establish‐
ment of the sessile community, and going as far as its detachment. The methodologies used
by the predominant amount of the present‐day studies search for the effects of sub‐MICs by
applying the tested agents during biofilm growth. It can be recommended that in the future a
more standardized methodology is applied which includes as well tests for dispersion of
established biofilms and for microbial vitality. The present review showed several critical
points in the effects of sub‐MICs of antibacterial substances as biofilm modulators. Among
these, the strain‐ and species‐specific responses of the bacteria in their biofilm development,
the expression of virulence factors and quorum sensing should necessarily be taken into
account when novel antibacterials are tested.
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